Insulet (PODD) Misses Q3 EPS by 7c

Insulet (NASDAQ: PODD) reported Q3 EPS of ($0.33), $0.07 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $87.3 million versus the consensus estimate of $83.56 million.

Guidance:

For the year ending December 31, 2015, the Company is raising the low end of its revenue expectations to a range of $310 to $320 million, from $305 to $320 million. This represents year-over-year revenue growth of 9% at the mid-point of the range.

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• Movano (MOVE) Misses Q2 EPS by 195c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c